Interleukin‐18 (IL‐18) is equally expressed in inflammatory breast cancer and noninflammatory locally advanced breast cancer: A possible association with chemotherapy response

Interleukin‐18 (IL‐18) is equally expressed in inflammatory breast cancer and noninflammatory locally advanced breast cancer: A possible association with chemotherapy response

Aim Inflammatory breast cancer (IBC) is the most aggressive form of locally advanced breast cancer. The signs of inflammation such as hyperemia and hyperthermia might suggest the possible participation of inflammatory mediators. This study investigates stromal and tumor expression of nuclear factor‐...

Full description

Saved in:
Bibliographic Details
Published in:Asia-Pacific journal of clinical oncology Vol. 14; no. 2; pp. e138 - e144
Main Authors: Aguiar, Marco Antonio Nasser, Wanderley, Carlos Wagner S., Nobre, Lívia Maria Soares, Alencar, Mateus Rolim Mendes, Saldanha, Maria do Perpétuo Socorro, Souza, Alceu Machado, Wong, Deysi Viviana Tenazoa, Barros, Paulo Goberlânio, Almeida, Paulo Roberto Carvalho, Lima‐Júnior, Roberto Cesar Pereira, Ribeiro, Ronaldo Albuquerque
Format: Journal Article
Language:English
Published: Australia Wiley Subscription Services, Inc 01-04-2018
Subjects:
Breast cancer
Chemotherapy
Cytokines
ErbB-2 protein
Hyperemia
Hyperthermia
Immunohistochemistry
Inflammation
inflammatory breast cancer
interleukin‐18 (IL‐18)
Mammography
Medical prognosis
non‐inflammatory locally advanced breast cancer
nuclear factor‐kappa B (NF‐κB)
Stroma
Tumor cells
inflammatory breast cancer
nuclear factor-kappa B (NF-κB)
non-inflammatory locally advanced breast cancer
interleukin-18 (IL-18)
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Inflammatory breast cancer (IBC) is the most aggressive form of locally advanced breast cancer. The signs of inflammation such as hyperemia and hyperthermia might suggest the possible participation of inflammatory mediators. This study investigates stromal and tumor expression of nuclear factor‐kappa B (NF‐κB) and interleukin‐18 (IL‐18) in samples obtained from IBC and noninflammatory locally advanced breast cancer (LABC) and the influence of these markers on patients' prognosis. Methods Demographic data, tumor molecular characteristics and overall survival in both groups were also assessed. Furthermore, in this study, we evaluated the expression of IL‐18 and p50 nuclear fraction of NF‐κB by immunohistochemistry in specimens from IBC and LABC (T4b). Results We observed that 24.6% of women were diagnosed with IBC up to age 40. In addition, the patients with IBC showed a lower overall survival when compared to LABC. In regard to molecular markers, ER+, C‐erbB2− or triple negative IBC patients showed a significantly reduced overall survival. In addition, a higher IL‐18 immunostaining in stroma of IBC and LABC was observed in comparison with tumor cells, but stromal immunoexpression was similar between IBC and LABC. Besides, IL‐18 positivity seemed be related with a better clinical response to neoadjuvant chemotherapy. However, NF‐κB expression was identical in both groups. Conclusion The IL‐18 is present in tumor stroma of IBC and LABC and seems to be associated with the complete response to neoadjuvant chemotherapy.
Bibliography:Conselho Nacional de Desenvolvimento Científico e Tecnológico, Grant Number: 307143/2014‐7, 458872/2014‐8; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Grant Number: CAPES‐PROEX 2862/2013; Fundação Cearense de Apoio ao Desenvolvimento Científico, Grant Number: PRONEX PR2‐0101‐00054.01.00/15; de Apoio ao Desenvolvimento Científico
Marco Antonio Nasser Aguiar and Carlos Wagner de S. Wanderley contributed equally to the development of this work.
Funding Information
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1743-7555
1743-7563
DOI:10.1111/ajco.12722